Card image cap
Budesonide helps reducing risk of pneumonia and death in COPD

Budesonide-based triple therapy is effective in reducing the risk of severe pneumonia and death in COPD patients, especially in those with higher blood eosinophil count, reveals a recent research. The findings of the study, published in the Journal of Chronic Obstructive Pulmonary Disease, used data from 29,716 new users of fluticasone-based triple therapy and 9646 new users of budesonide-based triple therapy, from the Clinical Practice Research Datalink. The research found that the incidence of a moderate or severe exacerbation and all-case death incidence was lower with budesonide-based triple therapy. 

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment